Get the Stockscreener App
2.55
0.39%
-0.01
Aytu Biopharma Inc stock is traded at $2.55, with a volume of 8,959.
It is down -0.39% in the last 24 hours and down -1.92% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.56
Open:
$2.52
24h Volume:
8,959
Relative Volume:
0.18
Market Cap:
$27.37M
Revenue:
$62.64M
Net Income/Loss:
$-24.56M
P/E Ratio:
-0.6643
EPS:
-3.8387
Net Cash Flow:
$-3.70M
1W Performance:
+1.19%
1M Performance:
-1.92%
6M Performance:
+17.51%
1Y Performance:
+135.02%
1-Day Range:
$2.47
$2.55
1-Week Range:
$2.47
$2.60
52-Week Range:
$1.06
$3.065
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.55 | 27.48M | 62.64M | -24.56M | -3.70M | -3.8387 |
TAK
Takeda Pharmaceutical Co Adr
|
16.41 | 51.68B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.65 | 49.57B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.47 | 42.18B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.62 | 36.40B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
569.11 | 24.85B | 3.18B | 1.33B | 1.04B | 27.90 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma, Inc. (AYTU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Aytu BioPharma Inc forming a double bottom2026 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
AYTU Stock Analysis: Aytu BioPharma Inc. biotech stock at 2.68 posts 1.52 percent daily gain - Cổng thông tin điện tử tỉnh Tây Ninh
Aytu BioPharma amends warrants to address accounting classification - Investing.com
Aytu BioPharma amends warrants to address accounting classification By Investing.com - Investing.com Canada
Aytu BioPharma Amends Investor Warrants to Restore Equity Classification and Reduce Liabilities - TradingView — Track All Markets
Aytu BioPharma (NASDAQ: AYTU) rewrites warrant terms to restore equity - Stock Titan
Aytu BioPharma Inc (AY20.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
AYTU PE Ratio & Valuation, Is AYTU Overvalued - Intellectia AI
What analysts say about Aytu BioPharma Inc stock2026 Support & Resistance & Weekly Top Stock Performers List - baoquankhu1.vn
AYTU Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Big Picture: Will Aytu BioPharma Inc benefit from rising consumer demandDip Buying & Stepwise Trade Signal Guides - baoquankhu1.vn
If You Invested $1,000 in Aytu Biopharma Inc (AYTU) - Stock Titan
History Review: What hedge funds are buying Aytu BioPharma Inc2026 Price Momentum & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Aytu BioPharma : Corporate Presentation March 2026 View Presentation Investor Day January 2026 View Presentation - marketscreener.com
Bull Run: Will Aytu BioPharma Inc benefit from rising consumer demand2026 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Aytu BioPharma, Inc. (AYTU) Competitors - Meyka
Will Aytu BioPharma Inc. stock deliver consistent dividendsJuly 2025 Levels & Consistent Growth Stock Picks - Naître et grandir
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
AYTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Is Aytu BioPharma Inc. forming a double bottomGlobal Markets & Intraday High Probability Alerts - mfd.ru
Is Aytu BioPharma Inc. stock a good pick for beginnersJuly 2025 Momentum & Low Risk High Win Rate Stock Picks - mfd.ru
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lytton, foundation report 9.99% Aytu BioPharma (AYTU) stake - Stock Titan
What is the cash position of Aytu BioPharma Inc.2025 Trading Recap & AI Forecasted Entry and Exit Points - mfd.ru
Panic Selling: What analysts say about Aytu BioPharma Inc stockMarket Trend Review & Safe Entry Zone Tips - baoquankhu1.vn
Breakouts Watch: What analysts say about Aytu BioPharma Inc stockMarket Risk Summary & High Accuracy Investment Signals - baoquankhu1.vn
Pharma News: Is Aytu BioPharma Inc. (AY20) stock testing key support2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Will Aytu BioPharma Inc. (AY20) stock benefit from infrastructure billRisk Management & Consistent Growth Stock Picks - mfd.ru
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):